Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLNO Soleno Therapeutics

Trading 05-13 15:23:25 EDT

52.97

+0.04

+0.08%

High52.98	Low52.93	Vol974.21K
Open52.95	D1 Closing52.93	Amplitude0.09%
Mkt Cap2.76B	Tradable Cap2.38B	Total Shares52.12M
T/O51.58M	T/O Rate2.17%	Tradable Shares44.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SLNO","market":"US","secType":"STK","nameCN":"Soleno Therapeutics","latestPrice":52.97,"timestamp":1778700205233,"preClose":52.93,"halted":0,"volume":974208,"delay":0,"changeRate":0.0007557150954090147,"floatShares":44870900,"shares":52120147,"eps":1.767046,"marketStatus":"Trading","change":0.04,"latestTime":"05-13 15:23:25 EDT","open":52.95,"high":52.98,"low":52.93,"amount":51581679.341568,"amplitude":0.000945,"askPrice":52.98,"askSize":2906,"bidPrice":52.97,"bidSize":2228,"shortable":3,"etf":0,"ttmEps":1.767046,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778702400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":52.93,"preHourTrading":{"tag":"盘前","latestPrice":52.96,"preClose":52.93,"latestTime":"09:29 EDT","volume":6127,"amount":324479.67046,"timestamp":1778678999999,"change":0.03,"changeRate":0.000567,"amplitude":0.000945},"postHourTrading":{"tag":"盘后","latestPrice":52.92,"preClose":52.93,"latestTime":"17:42 EDT","volume":7959,"amount":421272.48,"timestamp":1778622167318,"change":-0.01,"changeRate":-0.000189,"amplitude":0.000945},"volumeRatio":0.611727,"impliedVol":0.0727,"impliedVolPercentile":0.0159},"requestUrl":"/m/hq/s/SLNO/wiki","defaultTab":"wiki","newsList":[{"id":"2633107608","title":"Soleno Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633107608","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633107608?lang=en_us&edition=fundamental","pubTime":"2026-05-08 10:19","pubTimestamp":1778206754,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummarySoleno Therapeutics Inc SLNO.OQ reported quarterly adjusted earnings of 59 cents per share for the quarter ende","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L049:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633108732","title":"Soleno Q1 FY26 net income swings to USD 31.38 million; selling, general and administrative expense rises 72% to USD 50.37 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633108732","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633108732?lang=en_us&edition=fundamental","pubTime":"2026-05-08 06:00","pubTimestamp":1778191207,"startTime":"0","endTime":"0","summary":"Soleno Q1 FY26 net income swings to USD 31.38 million; selling, general and administrative expense rises 72% to USD 50.37 million. Soleno Therapeutics swung to net income of USD 31.38 million for quarter ended March 31, 2026, from a net loss of USD 43.77 million a year earlier.Product revenue, net reached USD 94.6 million, compared with no product revenue a year earlier, as VYKAT XR sales continued following FDA approval in March 2025.Operating income was USD 31.28 million, versus an operating loss of USD 45.74 million a year earlier, while selling, general and administrative expense climbed 72% to USD 50.37 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL26RGXZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","LU0154245673.USD","LU2324357040.USD","LU2065171402.SGD","LU0109394709.USD","LU2065170008.USD","LU0823416689.USD","LU0154245756.USD","LU0320765992.SGD","NBIX","SLNO","LU2065171311.SGD","BK4139","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633137816","title":"Neurocrine Posts Strong Q1 as Key Treatments Drive Growth, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2633137816","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633137816?lang=en_us&edition=fundamental","pubTime":"2026-05-06 23:25","pubTimestamp":1778081152,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences  delivered a strong Q1, powered by rising demand for  Ingrezza, its leading treatment for involuntary muscle movements, and an encouraging early launch of Crenessity, a new hormone-related therapy, Morgan Stanley said Wednesday in a report.Ingrezza demand is tracking above the company's 2026 guidance, supported by record new patient starts, durable persistence and no inventory effects or other one-time items in the quarter, the report said.Crenessity is a \"definitive blockbuster in the making\" with current sales reflecting only a fraction of its eventual potential as the launch remains early, Morgan Stanley said.Neurocrine's acquisition of Soleno Therapeutics  is expected to close around July 6, the report said.Morgan Stanley raised its price target on Neurocrine stock to $191 from $185 and maintained its equal-weight rating.Price: 145.19, Change: +10.13, Percent Change: +7.50","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0795875086.SGD","LU2089283258.USD","LU1244550577.SGD","LU0971096721.USD","LU0320765992.SGD","LU0234570918.USD","LU1244550221.USD","LU1791710400.SGD","LU1064131342.USD","BK4127","BK4581","LU0314104364.USD","LU2271345857.HKD","LU1363072403.SGD","LU0795875169.SGD","LU1162221912.USD","IE00BZ1G4Q59.USD","LU2065169927.USD","LU2065170008.USD","IE00BKVL7J92.USD","LU2028103732.USD","LU0320765646.SGD","LU2111349929.HKD","LU1732800096.USD","LU0158827781.USD","LU1791710582.SGD","LU2264538146.SGD","LU0106831901.USD","LU1732799900.SGD","MS","BK4516","LU0912757837.SGD","LU2357305700.SGD","LU0154245673.USD","LU0225283273.USD","LU0154245756.USD","LU0823416689.USD","NBIX","LU0158827948.USD","LU2065171402.SGD","LU2133065610.SGD","SLNO","LU1720051108.HKD","BK4588","LU0106261372.USD","LU0557290698.USD","LU0889565916.HKD","LU0882574139.USD","BK4139","LU1988902786.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633929332","title":"Neurocrine Biosciences Q1 adjusted EPS beats estimates, sales up 44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633929332","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633929332?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:15","pubTimestamp":1778012139,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences Q1 adjusted EPS beats estimates, sales up 44%OverviewU.S. biopharma firm's Q1 net product sales rose 44% yr/yr, driven by INGREZZA and CRENESSITYAdjusted EPS and adjusted net in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL1N41I19X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU2065171402.SGD","LU2324357040.USD","LU0823416689.USD","LU0154245673.USD","LU2065170008.USD","BK4139","LU2065171311.SGD","LU0320765992.SGD","NBIX","LU0154245756.USD","LU0889565916.HKD","LU2065169927.USD","SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633925153","title":"Neurocrine Q1 FY26 net income rises to $197.9 million; net product sales climb 44% to $811 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633925153","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633925153?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:02","pubTimestamp":1778011323,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences posted first-quarter results with net product sales rising 44% year over year to USD 811 million.GAAP net income came in at USD 197.9 million, lifting diluted EPS to USD 1.91.INGREZZA net product sales climbed 20% year over year to USD 656.9 million, while CRENESSITY net product sales reached USD 153.3 million.Announced definitive agreement to acquire Soleno Therapeutics for USD 53 per share in cash, valuing deal at USD 2.9 billion, expected to close in Q2 2026.Reaffirmed full-year 2026 INGREZZA net sales guidance of USD 2.7 billion to USD 2.8 billion.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL5CClpJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","LU0154245673.USD","LU2324357040.USD","LU2065171402.SGD","LU0109394709.USD","LU2065170008.USD","LU0823416689.USD","LU0154245756.USD","LU0320765992.SGD","NBIX","SLNO","LU2065171311.SGD","BK4139","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629904812","title":"Ema's Chmp: Application for Initial Marketing Authorisation Was Withdrawn for Viokat","url":"https://stock-news.laohu8.com/highlight/detail?id=2629904812","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629904812?lang=en_us&edition=fundamental","pubTime":"2026-04-24 17:51","pubTimestamp":1777024282,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nFWN4161D9:8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLNO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628788246","title":"Soleno Therapeutics call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2628788246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628788246?lang=en_us&edition=fundamental","pubTime":"2026-04-17 23:45","pubTimestamp":1776440713,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Soleno Therapeutics (SLNO) with 3,370 calls trading, 1.6x expected, and implied vol increasing over 1 point to 10.3...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-call-volume-above-normal-and-directionally-bullish-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-call-volume-above-normal-and-directionally-bullish-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628120166","title":"Soleno Therapeutics Cut to Equal-Weight From Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2628120166","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628120166?lang=en_us&edition=fundamental","pubTime":"2026-04-17 21:12","pubTimestamp":1776431520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SLNO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 17, 2026 09:12 ET (13:12 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628727491","title":"Soleno Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2628727491","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628727491?lang=en_us&edition=fundamental","pubTime":"2026-04-17 17:20","pubTimestamp":1776417640,"startTime":"0","endTime":"0","summary":"Wells Fargo downgraded Soleno Therapeutics (SLNO) to Equal Weight from Overweight with a price target of $53, down from $110. Published first on Th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-downgraded-to-equal-weight-from-overweight-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-downgraded-to-equal-weight-from-overweight-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626129719","title":"Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN), Viridian Therapeutics (VRDN) and Soleno Therapeutics (SLNO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626129719","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626129719?lang=en_us&edition=fundamental","pubTime":"2026-04-11 22:30","pubTimestamp":1775917808,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Enliven Therapeutics (ELVN), Viridian Therapeutics (VRDN) and Sol...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-enliven-therapeutics-elvn-viridian-therapeutics-vrdn-and-soleno-therapeutics-slno-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-enliven-therapeutics-elvn-viridian-therapeutics-vrdn-and-soleno-therapeutics-slno-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRDN","LABU","HCSG","XLV","BK4588","ELVN","SLNO","BK4585","BK4137","LU0029874061.USD","XBI","BK4581","LU0128526141.USD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625594500","title":"HC Wainwright Downgrades Soleno Therapeutics to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2625594500","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625594500?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:55","pubTimestamp":1775649301,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics (SLNO) has an average rating of hold and mean price target of $65.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625946804","title":"This Soleno Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2625946804","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625946804?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:50","pubTimestamp":1775649000,"startTime":"0","endTime":"0","summary":"Top Wall Street analysts changed outlook on top names. Check analyst ratings page for complete view. Consider buying SLNO stock, see analysts' views.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/08/Operations-Research-Analysts_0.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/08/Operations-Research-Analysts_0.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/downgrades/26/04/51700112/this-soleno-therapeutics-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-wednesday","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/downgrades/26/04/51700112/this-soleno-therapeutics-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BLSX","BLSG","BK4112","SLNO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625943940","title":"Soleno Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2625943940","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625943940?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:13","pubTimestamp":1775646780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SLNO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2026 07:13 ET (11:13 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625917255","title":"Soleno Therapeutics, Inc. : H.c. Wainwright Cuts to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2625917255","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625917255?lang=en_us&edition=fundamental","pubTime":"2026-04-08 18:07","pubTimestamp":1775642867,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nAZN4SPP9B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLNO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625959699","title":"Soleno Therapeutics downgraded to Neutral from Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2625959699","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625959699?lang=en_us&edition=fundamental","pubTime":"2026-04-07 22:19","pubTimestamp":1775571553,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi downgraded Soleno Therapeutics (SLNO) to Neutral from Overweight with a price target of $53, down from $145, a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-downgraded-to-neutral-from-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-downgraded-to-neutral-from-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2625995836","title":"Soleno Therapeutics Inc : Piper Sandler Cuts to Neutral From Overweight; Cuts Target Price to $53 From $145","url":"https://stock-news.laohu8.com/highlight/detail?id=2625995836","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625995836?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:24","pubTimestamp":1775564673,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40Q0WO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLNO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625930952","title":"Soleno Therapeutics : Oppenheimer Cuts to Perform From Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2625930952","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625930952?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:05","pubTimestamp":1775563510,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nAZN4SPGK5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLNO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625932291","title":"Soleno Therapeutics Inc : Stifel Cuts to Hold From Buy; Cuts Target Price to $53 From $115","url":"https://stock-news.laohu8.com/highlight/detail?id=2625932291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625932291?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:16","pubTimestamp":1775560619,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40Q0YT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625123932","title":"BUZZ-HC Wainwright lifts PT on Neurocrine after Soleno deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2625123932","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625123932?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:09","pubTimestamp":1775560168,"startTime":"0","endTime":"0","summary":"BUZZ-HC Wainwright lifts PT on Neurocrine after Soleno deal** Brokerage HC Wainwright reiterates U.S. drugmaker Neurocrine Biosciences NBIX.O at “buy”, raises PT to $215 from $192 after its deal to acquire Soleno Therapeutics SLNO.O ** Brokerage says the acquisition adds VYKAT XR, a newly approved treatment for extreme, uncontrollable hunger linked to a rare genetic condition, creating a second commercial growth engine** Brokerage adds Neurocrine’s endocrinology salesforce and payer reach could accelerate uptake beyond Soleno’s standalone trajectory** Brokerage expects the deal to diversify revenue away from Neurocrine’s movementdisorder drug Ingrezza as competition and patent risks increase over the longer term** Brokerage models VYKAT XR sales of $193 mln in 2026, ramping to more than $1 bln by 2031** As of last close, NBIX stock down 7% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"e0299e9c6e4b6a5c37b2b73f9463f0f4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nL4N40Q0PW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","BK4613","LU2361045086.USD","LU1720051017.SGD","LU2458330169.SGD","LU2065171311.SGD","LU2236285917.USD","LU1046421795.USD","LU0353189763.USD","CRMG","IE00BKVL7J92.USD","LU1791710400.SGD","LU1823568750.SGD","BK4608","LU0820562030.AUD","LU0648000940.SGD","LU0689626769.HKD","LU0980610538.SGD","LU2361044865.SGD","LU0742534661.SGD","IE00B19Z8W00.USD","LU1951200564.SGD","NBIX","LU1316542783.SGD","LU1548497426.USD","BK4581","LU0320765992.SGD","LU0124676726.USD","BK4579","LU0889565833.HKD","LU0198837287.USD","LU0109392836.USD","LU0130517989.USD","LU0082616367.USD","LU1201861249.SGD","LU1804176565.USD","BK4023","BK4543","IE00BZ1G4Q59.USD","IE00BQXX3C00.GBP","LU0289739343.SGD","LU2357305700.SGD","LU1923623000.USD","LU1814569148.SGD","LU0106261372.USD","LU2065170008.USD","LU0154245756.USD","LU0130518102.USD","LU0238689110.USD","LU0511384066.AUD","LU2065171402.SGD","IE00B19Z9505.USD","LU0251131958.USD","LU1366333091.USD","LU2247934214.USD","IE00BQXX3D17.EUR","LU0823416689.USD","LU1951198990.SGD","LU0642271901.SGD","LU1791710582.SGD","BK4585","LU1720051108.HKD","LU0081259029.USD","BK4534","LU0267386448.USD","LU1201861165.SGD","LU1267930490.SGD","LU0889566641.SGD","LU0792757196.USD","LU0154245673.USD","LU0354030438.USD","LU0354030511.USD","BK4588","LU0109394709.USD","LU0234572021.USD","LU0048573561.USD","LU0528227936.USD","LU0689472784.USD","LU0648001328.SGD","LU1803068979.SGD","BK4527","LU0157215616.USD","IE00B19Z8X17.USD","LU1551013425.SGD","BK4535","LU0069063385.USD","LU1551013342.USD","BK4139","LU0477156797.USD","IE00BJTD4N35.SGD","LU0130102774.USD","LU1235294995.USD","LU2361044949.HKD","BK4550","LU2756315318.SGD","LU0211327993.USD","LU0820561818.USD","LU1064131342.USD","BK4505","LU0211328371.USD","LU2286300806.USD","LU2324357040.USD","LU2265009873.SGD","LU0251142724.SGD","SLNO","LU0353189680.USD","LU2458330243.SGD","LU1267930813.SGD","BK4607","LU0006306889.USD","LU0310799852.SGD","IE00BJTD4V19.USD","LU0057025933.USD","LU2461242641.AUD","BK4532","BK4598","LU0889565916.HKD","LU1496350502.SGD","LU1989764664.SGD","LU0289961442.SGD","BK4567","IE00BQXX3F31.USD","LU0943347566.SGD","BK4538","LU2264538146.SGD","BK4528","BK4561","LU1988902786.USD","LU0130103400.USD","LU0477156953.USD","LU1496350171.SGD","LU0234570918.USD","LU0472753341.HKD","LU0127658192.USD","LU0557290698.USD","LU2756315664.SGD","LU2244417387.USD","BK4548","LU0820561909.HKD","LU1989764748.USD","LU0187121727.USD","LU2087625088.SGD","LU0719512351.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625932124","title":"BRIEF-Soleno Therapeutics Inc - Withdraws Marketing Authorization Application For Viokat In Europe - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2625932124","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625932124?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:09","pubTimestamp":1775560150,"startTime":"0","endTime":"0","summary":"BRIEF-Soleno Therapeutics Inc - Withdraws Marketing Authorization Application For Viokat In Europe - SEC FilingApril 7 (Reuters) - Soleno Therapeutics Inc SLNO.O:SOLENO THERAPEUTICS INC - WITHDRAWS MA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40P0M3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLNO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.soleno.life","stockEarnings":[{"period":"1week","weight":0.0002},{"period":"1month","weight":0.0057},{"period":"3month","weight":0.3216},{"period":"6month","weight":0.1178},{"period":"1year","weight":-0.3099},{"period":"ytd","weight":0.1432}],"compareEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":0.0864},{"period":"3month","weight":0.0668},{"period":"6month","weight":0.0984},{"period":"1year","weight":0.2662},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.026118},{"month":2,"riseRate":0.333333,"avgChangeRate":0.234502},{"month":3,"riseRate":0.583333,"avgChangeRate":-0.004811},{"month":4,"riseRate":0.5,"avgChangeRate":0.094189},{"month":5,"riseRate":0.583333,"avgChangeRate":0.068121},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.071619},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.051924},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.014863},{"month":9,"riseRate":0.454545,"avgChangeRate":0.409781},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.115533},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.012609},{"month":12,"riseRate":0.333333,"avgChangeRate":0.051862}],"exchange":"NASDAQ","name":"Soleno Therapeutics","nameEN":"Soleno Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Soleno Therapeutics(SLNO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Soleno Therapeutics,SLNO,Soleno Therapeutics股票,Soleno Therapeutics股票老虎,Soleno Therapeutics股票老虎国际,Soleno Therapeutics行情,Soleno Therapeutics股票行情,Soleno Therapeutics股价,Soleno Therapeutics股市,Soleno Therapeutics股票价格,Soleno Therapeutics股票交易,Soleno Therapeutics股票购买,Soleno Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Soleno Therapeutics(SLNO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction